Navigation Links
Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
Date:12/5/2008

SAN DIEGO, Dec. 5 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX) today announced changes to conserve the Company's resources, focus its efforts on its late-stage obesity programs and realign its management team.

The key aspects of these changes are as follows:

-- The exploratory proof-of-concept Phase 2 trials for OREX-003 (zonisamide and olanzapine to mitigate antipsychotic-associated weight gain) and OREX-004 (fluoxetine and naltrexone to reduce symptoms of obsessive- compulsive disorder) will be discontinued effective immediately. The Company intends to maintain its intellectual property in these assets and retains the option to reinitiate these programs in the future.

-- Dr. Gary Tollefson has resigned as Director, President and Chief Executive Officer of the Company as of December 4, 2008, ending his previously announced leave of absence, and has elected to focus on his continued recovery from a previously disclosed diagnosis of acute leukemia. Orexigen has retained an executive search firm to assist it in finding a new, permanent CEO. In addition, Anthony McKinney, the Company's Chief Business Officer, and Frank Bymaster, the Company's Vice President of Neuroscience, will be leaving the Company effective as of today to pursue other opportunities. Dr. Michael Cowley, the Company's Chief Scientific Officer, will be stepping down from this position, but will transition to a consultant to the Company.

"While our balance sheet remains strong, the Company recognizes the challenges of the current economic environment and the need to focus our resources on our late-stage obesity programs," said Eckard Weber, M.D., the Company's Interim President and Chief Executive Officer and Executive Chairman. "I would like to thank Gary, along with the other members of the de
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
2. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
8. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX ), ... serving the pharmaceutical, biotechnology, and medical device industries, with ... the United States , today announced the ... Tel Aviv area of Israel.  ... of integrated R&D services to local customers. It will ...
(Date:10/30/2014)... , Oct. 30, 2014  The number of ... is growing steadily, thanks to drug store ... a result of the economic downturn, retail clinic growth ... year of opportunities, as the number of retail clinics ... report, Retail Clinics Market Overview and 2014 Consumer ...
(Date:10/30/2014)...   BioLife Solutions , Inc. (NASDAQ: ... proprietary clinical grade hypothermic storage and ... products for cells and tissues, today announced today ... be released on Thursday, November 6, 2014, and that ... webcast at 1:30 p.m. PST that afternoon. Management will ...
Breaking Medicine Technology:WuXi AppTec Launches Representative Office in Israel, Forms Strategic Collaboration with Pontifax 2Report: Drugstore Chains Drive Retail Clinic Growth 2Report: Drugstore Chains Drive Retail Clinic Growth 3BioLife Solutions to Report Financial Results for Third Quarter 2014 and Provide Business Update on November 6, 2014 2
... Inc . announced today that David A. Weber, Ph.D. , ... Board of Directors. Jay Lichter, Ph.D., managing director of Avalon Ventures, ... actively support the company as a member of the Board of ... to the Otonomy team, as his extensive experience in the development ...
... 2010 Amicus Therapeutics (Nasdaq: FOLD ), ... diseases, today announced that it has been awarded a ... Parkinson,s Research (MJFF) for the development of a novel, ...  The $500,000 award will be distributed over a period ...
Cached Medicine Technology:Otonomy Appoints David A. Weber, Ph.D., Chief Executive Officer 2Otonomy Appoints David A. Weber, Ph.D., Chief Executive Officer 3Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease 2Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease 3Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease 4Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease 5
(Date:10/30/2014)... October 30, 2014 Home Care Assistance ... provider of non-medical, in-home senior care, is weighing in ... brain health. , The study, performed by the University ... 60 and 78 over a week-long period and observed ... daily physical activity. By examining the structural soundness of ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 ... Commission Accredited teleradiology and specialty telemedicine solutions provider, ... addition to its existing teleradiology services at Mission ... opinion and expert telemedicine services, to the state-of-the-art, ... As a result of this innovative partnership, there ...
(Date:10/30/2014)... The Woodlands, TX (PRWEB) October 30, 2014 ... hospital system, released today its 2014 third quarter ... hospitals across Texas boasted infection rates of only ... also reported patient satisfaction scores exceeding 98 percent. ... this past quarter, which included rising satisfaction scores,” ...
(Date:10/30/2014)... HealthDay Reporter WEDNESDAY, Oct. ... chemical during pregnancy may have effects on genital development in ... baby boys born to moms with greater exposure to a ... -- the space between the genitals and anus. Anogenital distance ... of exposure to androgens ("male" hormones) during pregnancy. The ...
(Date:10/30/2014)... WEDNESDAY, Oct. 29, 2014 (HealthDay News) -- Americans, opinions ... political lines, a new study finds. Democratic voters ... (ACA), according to the researchers. Almost three-quarters of Democrats ... ACA. Thirty percent want Congress to implement the current ... of the ACA. Among Independent voters, one-third want ...
Breaking Medicine News(10 mins):Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 2Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 3Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 2Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 3Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 2Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 3Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 2Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 3Health News:Voters' Views on Obamacare Split Along Party Lines 2
... , , , ... CareFusion Corporation, the company that will become publicly traded following ... of Cardinal Health, today announced it has expanded its Pyxis((R)) ... (ORIS), incorporate radio-frequency identification (RFID) technology(1) and include new services. ...
... , , MENTOR, Ohio, July 20 ... issue its fiscal 2010 first quarter earnings before the market opens on ... time. The conference call can be heard live over the Internet at ... the United States and Canada, and 1-773-799-3378 internationally, then referencing the password ...
... , CHAPEL HILL, N.C., July 20 RealMed ... partnership to provide RealMed EDI Revenue Management Services to clients ... RealMed will provide services including online ECS claims filing, editing ... Eligibility Verification). In return, TSI Healthcare has committed ...
... The PBCC Announces availability of conference scholarships ... for the 2009 PA Breast Cancer Coalition Annual Conference , ... Coalition (PBCC) is proud to announce the availability of scholarships and travel grants for ... at the Harrisburg Hilton & Towers on Wednesday, October 14, 2009. , ...
... , , SKILLMAN, ... octuplets Nadya Suleman and "Jon & Kate Plus 8" has American ... fertilization (IVF). The recent e.p.t((R)) /BabyCenter ((R)) Fertility Report* ... believe that public visibility of large families and multiple births are ...
... , HOUSTON, July 20 What will healthcare look ... If you would like to learn more and have an opportunity to make ... morning-long forum on "Building a Federal Health Board: The Impact on Texas." ... St. Joseph Medical Center, 1401 St. Joseph Parkway in Houston, Texas on Wednesday, ...
Cached Medicine News:Health News:CareFusion Expands Pyxis(R) Perioperative Solutions Offering 2Health News:CareFusion Expands Pyxis(R) Perioperative Solutions Offering 3Health News:CareFusion Expands Pyxis(R) Perioperative Solutions Offering 4Health News:CareFusion Expands Pyxis(R) Perioperative Solutions Offering 5Health News:STERIS Corporation Announces Date of Fiscal 2010 First Quarter Earnings Release and Conference Call 2Health News:STERIS Corporation Announces Date of Fiscal 2010 First Quarter Earnings Release and Conference Call 3Health News:RealMed Corporation and TSI Healthcare Announce Strategic Partnership 2Health News:Scholarships Available for PA Breast Cancer Coalition Annual Conference 2Health News:New e.p.t.(R)/BabyCenter(R) Fertility Report Reveals 70 Percent of Moms Want Tighter Regulation on In-Vitro Fertilization 2Health News:New e.p.t.(R)/BabyCenter(R) Fertility Report Reveals 70 Percent of Moms Want Tighter Regulation on In-Vitro Fertilization 3Health News:New e.p.t.(R)/BabyCenter(R) Fertility Report Reveals 70 Percent of Moms Want Tighter Regulation on In-Vitro Fertilization 4Health News:Building a Federal Health Board - Impact on Texas 2
Designed to give maximum drying area while taking up minimal bench space....
Used to remove wrinkles from sections and for reorientating embedded tissue....
Compact instrument that quickly dries racks of slides using warm air....
Liquichek Blood Gas Plus CO-Oximeter Control (IL Synthesis Series) is a combination control for use in monitoring the performance of blood gas, ion-selective electrode, biosensor and CO-Oximetry anal...
Medicine Products: